UQCRB and central nervous system cancer: For example, synthetic small-molecule inhibitors of ubiquinol-cytochrome c reductase binding protein (UQCRB) in Complex III blocked neurosphere formation in two glioma cell lines, and OXPHOS inhibitor treatment of neurospheres led to the downregulation of c-Met, STAT3, Akt, and TIC markers CD133, OCT4, Nanog, and SOX2 [29].